A pilot study of 2% tofacitinib cream with narrowband ultraviolet B for the treatment of facial vitiligo - 27/07/19
Doi : 10.1016/j.jaad.2019.04.032
Jacqueline McKesey, MD, Amit G. Pandya, MD ⁎ 
Department of Dermatology, University of Texas Southwestern Medical Center, Dallas, Texas
∗Correspondence to: Amit G. Pandya, MD, Department of Dermatology, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, Texas, 75390-9069Department of DermatologyUniversity of Texas Southwestern Medical Center5323 Harry Hines BlvdDallasTexas75390-9069
| Funding sources: None. |
|
| Conflicts of interest: Dr Pandya is a consultant for Pfizer, maker of tofacitinib, and serves as the principal investigator for a vitiligo study with a new drug funded by Pfizer. Dr McKesey has no conflicts of interest to disclose. |
|
| Reprints not available from the authors. |
© 2019
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 81 - N° 2
P. 646-648 - août 2019 Retour au numéro
Article précédent
- Low-dose naltrexone therapy in benign chronic pemphigus (Hailey-Hailey disease): A case series
- Constanza Riquelme-Mc Loughlin, José Riera-Monroig, Daniel Morgado-Carrasco, Priscila Giavedoni, Sebastian Podlipnik, Pilar Iranzo, José M. Mascaró
- Effectiveness and safety of low-dose oral minoxidil in male androgenetic alopecia
- Juan Jimenez-Cauhe, David Saceda-Corralo, Rita Rodrigues-Barata, Angela Hermosa-Gelbard, Oscar M. Moreno-Arrones, Diego Fernandez-Nieto, Sergio Vaño-Galvan
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?